Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2026 | Evolution of care bundles in acute intracerebral hemorrhage: insights from INTERACT3 to I-CATCHER

Craig Anderson, MD, PhD, The George Institute for Global Health, Sydney, Australia, discusses the evolution of care bundles in acute intracerebral hemorrhage (ICH). Prof. Anderson explains that rather than selecting patients for treatment based on benefit over risk, care bundles group several low-risk interventions with plausible benefit. He highlights that the INTERACT3 trial (NCT03209258) established the benefit of a care bundle and he explains that the ongoing I-CATCHER trial (NCT06429332) is now evaluating an extended bundle. This interview took place at the 18th World Stroke Congress (WSC) in Seoul, Korea.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

In my talk today was to give an overview of the evolution and current status of care bundles in acute intracerebral hemorrhage. And I started by defining what we actually mean by a care bundle. It’s the grouping of several interventions with generally an agreed benefit to the patient with low risk. These could be benefits established in randomized controlled trials or observational studies, which seem reasonable as a grouping that could be applied consistently across most patients in clinical practice...

In my talk today was to give an overview of the evolution and current status of care bundles in acute intracerebral hemorrhage. And I started by defining what we actually mean by a care bundle. It’s the grouping of several interventions with generally an agreed benefit to the patient with low risk. These could be benefits established in randomized controlled trials or observational studies, which seem reasonable as a grouping that could be applied consistently across most patients in clinical practice. Traditionally, we select patients for a treatment based on benefit over risk, but here it’s a grouping of interventions with low risk with plausible benefit. And in intracerebral hemorrhage, we’ve shown the benefit of bundling up early intensive blood pressure lowering, glycemic control, treatment of pyrexia, and early reversal of anticoagulation. That care bundle was definitively established in the INTERACT3 trial a few years ago, but that trial was conducted primarily in low- and middle-income countries. There was a little bit of uncertainty about how the interventions worked to affect the outcome. For example, very few patients got warfarin anticoagulation. No one got reversal of a direct oral anticoagulant. So we also need to get more evidence in high-income countries, perhaps with a more extended care bundle, which is actually what’s going on at the moment with an international trial called I-CATCHER. It was built on INTERACT3 with a more extended care bundle that includes avoidance of early do not resuscitate orders, direct pathways from neurosurgery and intensive care management, and more aggressive monitoring of the patient, including early repeat CT imaging to get a better measure of hematoma expansion.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.